Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 15/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034490 | 0.85 | LMNA (0.45) | SLC6A2SLC6A4SLC6A3LMNACYP2D6 | |
| SCHEMBL979064 | 0.80 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL4029586 | 0.77 | SLC6A4 (0.56) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL981084 | 0.77 | OPRK1 (0.52) | LMNACYP2D6GAA | |
| SCHEMBL980297 | 0.76 | PYCR1 (0.43) | LMNALPAR1NPC1RAB9A | |
| SCHEMBL5629271 | 0.75 | LMNA (0.55) | LMNAGAA | |
| SCHEMBL980130 | 0.70 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL4028989 | 0.69 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL4031996 | 0.68 | HTT (0.49) | LMNACYP2D6NPC1RAB9AGAA | |
| Fumaric Acid SCHEMBL5997512 | 0.67 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838315-B1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHODS FOR PRODUCING THEM, THEIR USE AS DRUG, AND DRUG CONTAINING THEM | SANOFI SA (FR) | 2014-03-12 | — | — | EP | disclosed |
| US-7868003-B2 | Substituted 4-phenyltetrahydroisoquinolines, pharmaceutical compositions comprising them and therapeutic methods for their use | SANOFI-AVENTIS (FR) | 2011-01-11 | — | — | US | disclosed |
| US-20080058328-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, PHARMACEUITCAL COMPOSITIONS COMPRISING THEM AND THERAPEUTIC METHODS FOR THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| EP-1838315-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHODS FOR PRODUCING THEM, THEIR USE AS DRUG, AND DRUG CONTAINING THEM | sanofi-aventis (FR) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006074813-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHODS FOR PRODUCING THEM, THEIR USE AS DRUG, AND DRUG CONTAINING THEM | SANOFI-AVENTIS (DE) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058328-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, PHARMACEUITCAL COMPOSITIONS COMPRISING THEM AND THERAPEUTIC METHODS FOR THEIR USE | REN, MTNR1B, MTNR1A | SLC6A2 651/4885SLC6A4 374/4885SLC6A3 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.